Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Baloxavir Marboxil→

Baloxavir Marboxil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1985606-14-1
Molecular formula
C27H23F2N3O7S
Molecular weight
571.6 g/mol
Drug class
Antiviral prodruginfluenza virus cap-dependent endonuclease inhibitor precursor
Mechanism of action
Baloxavir marboxil is converted to baloxavir acid, which inhibits the cap-dependent endonuclease of the influenza virus polymerase acidic (PA) protein, preventing viral mRNA synthesis and replication.
Indications / reported uses
  • Treatment of acute uncomplicated influenza in patients aged 5 years and older who are otherwise healthy or at high risk of influenza complications under the US label
  • Post-exposure prophylaxis of influenza in eligible patients aged 5 years and older; product- and jurisdiction-specific

Sources: US DailyMed — XOFLUZA · FDA — XOFLUZA label · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Antiviral prodrug; influenza virus cap-dependent endonuclease inhibitor precursor

Mechanism of action

Baloxavir marboxil is converted to baloxavir acid, which inhibits the cap-dependent endonuclease of the influenza virus polymerase acidic (PA) protein, preventing viral mRNA synthesis and replication.

General use cases

  • Treatment of acute uncomplicated influenza in patients aged 5 years and older who are otherwise healthy or at high risk of influenza complications under the US label
  • Post-exposure prophylaxis of influenza in eligible patients aged 5 years and older; product- and jurisdiction-specific

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Baloxavir Marboxil Environmental Risk Assessment (ERA) (the Baloxavir Marboxil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.